<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">FASEB J</journal-id><journal-id journal-id-type="iso-abbrev">FASEB J</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</journal-title></journal-title-group><issn pub-type="ppub">0892-6638</issn><issn pub-type="epub">1530-6860</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10372847</article-id><article-id pub-id-type="pmcid-ver">PMC10372847.319</article-id><article-id pub-id-type="pmcaid">10372847</article-id><article-id pub-id-type="pmcaiid">10372847</article-id><article-id pub-id-type="manuscript-id">NIHMS1915881</article-id><article-id pub-id-type="pmid">37482902</article-id><article-id pub-id-type="doi">10.1096/fj.202300671R</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1915881</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1915881</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Blockade of the Mineralocorticoid Receptor Improves Markers of Human Endothelial Cell Dysfunction and Hematological Indices in a Mouse Model of Sickle Cell Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rivera</surname><given-names initials="A">Alicia</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vega</surname><given-names initials="C">Christopher</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramos-Rivera</surname><given-names initials="A">Arelys</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maldonado</surname><given-names initials="ER">Enrique R.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prado</surname><given-names initials="GN">Gregory N.</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karnes</surname><given-names initials="HE">Hope E.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fesko</surname><given-names initials="YA">Yuri A.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Snyder</surname><given-names initials="LM">L. Michael</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alper</surname><given-names initials="SL">Seth L.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Romero</surname><given-names initials="JR">Jose R.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Nephrology, Vascular Biology Research Center, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA</aff><aff id="A2"><label>2</label>Departments of Laboratory Medicine and Pathology, Boston Children&#8217;s Hospital, Harvard Medical School, Boston, MA</aff><aff id="A3"><label>3</label>Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women&#8217;s Hospital and Harvard Medical School, Boston, MA</aff><aff id="A4"><label>4</label>Quest Diagnostics, Secaucus, NJ</aff><author-notes><corresp id="CR1">To whom correspondence should be addressed: Dr. Alicia Rivera, Beth Israel Deaconess Medical Center, 99 Brookline Ave. Building RN 380A, Boston, MA 02215, USA. <email>arivera3@bidmc.harvard.edu</email></corresp><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">Equal contributions</p></fn><fn fn-type="con" id="FN2"><p id="P2">Author Contributions</p><p id="P3">This study was conceived and designed by AR and JRR. Data collection and assembly were conducted by CV, ARR, ERM, and GNP. Data were analyzed and interpreted by AR, CV, GNP, SLA, and JRR. The manuscript was written by AR, JRR, and SLA and revised by AR, CV, ARR, ERM, GNP, HEK, YAF, LMS, SLA and JRR. All authors approved the final version of the manuscript.</p></fn><fn fn-type="COI-statement" id="FN3"><p id="P45">Conflicts of interest</p><p id="P46">YAF and HEK are employees and stockholders of Quest Diagnostics Inc.</p><p id="P47">SLA and LMS are consultants to Quest Diagnostics Inc.</p><p id="P48">SLA received research support from Quest Diagnostics Inc.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2023</year></pub-date><volume>37</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">441649</issue-id><fpage>e23092</fpage><lpage>e23092</lpage><pub-history><event event-type="nihms-submitted"><date><day>13</day><month>07</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-29 13:25:50.140"><day>29</day><month>08</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1915881.pdf"/><abstract id="ABS1"><p id="P4">Increased endothelin-1 (ET-1) levels in patients with sickle cell disease (SCD) and transgenic mouse models of SCD contribute to disordered hematological, vascular, and inflammatory responses. Mineralocorticoid receptor (MR) activation by aldosterone, a critical component of the Renin-Angiotensin-Aldosterone-System, modulates inflammation and vascular reactivity, partly through increased ET-1 expression. However, the role of MR in SCD remains unclear. We hypothesized that MR blockade in transgenic SCD mice would reduce ET-1 levels, improve hematological parameters, and reduce inflammation. Berkeley SCD (BERK) mice, a model of severe SCD, were randomized to either sickle standard chow or chow containing the MR antagonist (MRA), eplerenone (156 mg/Kg), for 14 days. We found that MRA treatment reduced ET-1 plasma levels (p=0.04), improved red cell density gradient profile (D<sub>50</sub>; p&lt;0.002), and increased mean corpuscular volume in both erythrocytes (p&lt;0.02) and reticulocytes (p&lt;0.024). MRA treatment also reduced the activity of the erythroid intermediate-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel &#8211; K<sub>Ca</sub>3.1 (Gardos channel, <italic toggle="yes">KCNN4</italic>), reduced cardiac levels of mRNAs encoding ET-1, Tumor Necrosis Factor Receptor-1, and Protein Disulfide Isomerase (PDI) (p&lt;0.01), and decreased plasma PDI and myeloperoxidase activity. Aldosterone (10<sup>&#8722;8</sup> M for 24 h <italic toggle="yes">in vitro</italic>) also increased PDI mRNA levels (p&lt;0.01) and activity (p&lt;0.003) in EA.hy926 human endothelial cells, in a manner blocked by pre-incubation with the MRA canrenoic acid (1 &#956;M; p&lt;0.001). Our results suggest a novel role for MR activation in SCD that may exacerbate SCD pathophysiology and clinical complications.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P5">Schematic representation of the interaction of aldosterone (ALDO) and endothelin-1 (ET-1) in sickle cell disease. In endothelial cells, aldosterone binds to the mineralocorticoid receptor (MR), leading to increased ET-1 and ROS production and secretion and activating the endothelium. Plasma ET-1 binds to red cell endothelin B receptors (ETRB), increasing K<sup>+</sup> efflux, driving red cell water loss and shrinkage, leading to increased Hb S polymerization and red cell sickling, entrapment, and further endothelial cell activation. The mineralocorticoid receptor antagonist (MRA), eplerenone, blocks MR. ETA, endothelin-1 receptor antagonists; RBC, red blood cells; Hb S: hemoglobin S; PDI, protein disulfide isomerase.</p></abstract><kwd-group><kwd>Protein disulfide isomerase</kwd><kwd>Endothelin-1</kwd><kwd>Sickle Cell Disease</kwd><kwd>Mineralocorticoid Receptor</kwd><kwd>Eplerenone</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>